Case Report: Hepatic sarcoidosis-like reaction from neoadjuvant pembrolizumab in early-stage triple-negative breast cancer
Drug-induced sarcoidosis-like reaction (DISR) is a rare adverse event associated with immunotherapy. Currently, there is no standardized treatment protocol for DISR linked to immune checkpoint inhibitors (ICIs). This study presents a case of an early-stage triple-negative breast cancer (TNBC) patient who developed hepatic sarcoidosis-like reactions during neoadjuvant pembrolizumab therapy. We provide an overview of ICI-induced sarcoidosis-like reactions in cancer patients, including incidence, mechanisms, clinical manifestations, treatment, and prognosis. Additionally, we discuss the significance of one-year adjuvant immunotherapy for early-stage TNBC patients who achieved pathological complete response after neoadjuvant therapy, offering insights for individualized therapeutic strategies in this population.
Authors
- Fei Ma (ORCID: https://orcid.org/0000-0001-9432-1902)
- Aihua Zhu (ORCID: https://orcid.org/0000-0001-7535-5648)
- Yujing Tan (ORCID: https://orcid.org/0000-0001-8781-1209)
- Xiaoyan Liu (ORCID: https://orcid.org/0000-0002-2409-8941)
- Yu Wang (ORCID: https://orcid.org/0000-0001-7811-5834)
- Qin Ma
- Jiani Wang (ORCID: https://orcid.org/0000-0002-0869-3468)
- Cheng Zeng (ORCID: https://orcid.org/0000-0002-7327-7807)
- Xiaoying Sun (ORCID: https://orcid.org/0000-0003-4180-2766)
Institutions
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- National Cancer Center (US)
- Shanxi Provincial Cancer Hospital (CN)
- Cancer Hospital of Huanxing Chaoyang District Beijing (CN)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2025-06-18
- DOI
- https://doi.org/10.3389/fimmu.2025.1589191
- Citations
- 2
- Primary Topic
- Sarcoidosis and Beryllium Toxicity Research
- Type
- article
- Field-Weighted Citation Impact
- 2.33
Funders
- National Natural Science Foundation of China